Hsbc Holdings PLC Raises Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Hsbc Holdings PLC raised its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 66.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 38,690 shares of the company's stock after buying an additional 15,465 shares during the period. Hsbc Holdings PLC's holdings in IDEAYA Biosciences were worth $980,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Rhumbline Advisers lifted its holdings in IDEAYA Biosciences by 0.5% in the fourth quarter. Rhumbline Advisers now owns 113,561 shares of the company's stock valued at $2,919,000 after acquiring an additional 585 shares during the period. Daiwa Securities Group Inc. lifted its stake in shares of IDEAYA Biosciences by 44.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock worth $72,000 after purchasing an additional 853 shares during the period. Mariner LLC lifted its stake in shares of IDEAYA Biosciences by 9.8% in the 4th quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after purchasing an additional 869 shares during the period. Assetmark Inc. boosted its holdings in shares of IDEAYA Biosciences by 2.5% in the fourth quarter. Assetmark Inc. now owns 45,269 shares of the company's stock worth $1,163,000 after buying an additional 1,084 shares during the last quarter. Finally, R Squared Ltd bought a new stake in IDEAYA Biosciences during the fourth quarter valued at approximately $35,000. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Stock Performance

IDYA stock opened at $20.93 on Friday. The company's fifty day moving average price is $17.90 and its 200-day moving average price is $23.05. IDEAYA Biosciences, Inc. has a one year low of $13.45 and a one year high of $44.42. The company has a market capitalization of $1.83 billion, a PE ratio of -6.34 and a beta of 0.26.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The firm had revenue of $7.00 million during the quarter, compared to analysts' expectations of $7.00 million. On average, research analysts predict that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Royal Bank of Canada reiterated an "outperform" rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Finally, Stephens restated an "overweight" rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $53.58.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

Want to see what other hedge funds are holding IDYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.